dc.creatorPoniachik Teller, Jaime
dc.creatorQuera Pino, Rodrigo
dc.creatorLui G., Andrea
dc.date.accessioned2019-01-29T17:51:14Z
dc.date.available2019-01-29T17:51:14Z
dc.date.created2019-01-29T17:51:14Z
dc.date.issued2002
dc.identifierRevista Medica de Chile, Volumen 130, Issue 6, 2018, Pages 691-698
dc.identifier00349887
dc.identifierhttps://repositorio.uchile.cl/handle/2250/163543
dc.description.abstractFulminant hepatic failure (FHF) is an acute and eventually fatal illness, caused by a severe hepatocyte damage with massive necrosis. Its hallmarks are hepatic encephalopathy and a prolonged prothrombin time (<40%). FHF is currently defined as hyperacute (encephalopathy appearing within 7 days of the onset of jaundice), acute (encephalopathy appearing between 8 and 28 days) or subacute (encephalopathy appearing between 5 and 12 weeks). FHF can be caused by viruses, drugs, toxins, and miscellaneous conditions such as Wilson's disease, Budd-Chiari syndrome, ischemia and others. However, a single most common etiology is still not defined. Factors that are valuable in assessing the likelihood of spontaneous recovery are age, etiology, degree of encephalopathy, prothrombin time and serum bilirubin. The management is based in the early treatment of infections, hemodynamic abnormalities, cerebral edema, and other associated conditions. Liver transplant has emerged as the most important advanc
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceRevista Medica de Chile
dc.subjectHepatic encephalopathy
dc.subjectHepatic failure, fulminant
dc.subjectHypoprothrombinemia
dc.subjectLiver transplantation
dc.subjectProthrombin
dc.titleFulminant hepatic failure Insuficiencia hepática fulminante
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución